Cite
HARVARD Citation
Vernieri, F. et al. (2023). Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study. European journal of neurology. pp. 224-234. [Online].